Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-202

I agree. Weare going to know the results very quickly based on the mouse trials, I wouldsay from day 40. If they proceeds and recruit very quickly and move through the dose escalation cohorts and is announced publicly then Imugene will know they are onto something with OnCARlytics.

If you lookat the trial design published for the ASCO conference, the second part of the studyDose Escalation Combination Phase (which is where we are now),Blinatumomab is given to the patient on Day 2 continuously for 7 days, 1 weekoff for both CF33-CD19 and Blinatumomab, then repeat. 1 cycle for the combinationescalation is 28 days v the monotherapy escalation being 21 days for 1 cycle (2doses for CD-CD19). Note Blinatumomab is only given in 1 cycle for the OASIStrials (1^st dose 9micrograms and 2^nd dose 28micrograms). Hopefullythere’s enough payload in the missiles to do something to the solid tumors.Standard treatment for B cell (ALL) is up to 5 cycles. Patients who are incomplete remission after 2 cycles of induction treatment may receive up to 3additional cycles of consolidation treatment, based on an individualbenefit-risk assessment. Blinatumomab in NSW is so expensive @ AUD $77,360 per cycle.

https://www.eviq.org.au/haematology-and-bmt/leukaemias/acute-lymphoblastic-leukaemia/3404-acute-lymphoblastic-leukaemia-blinatumomab#:~:text=A%20single%20cycle%20of%20treatment,week)%20treatment%2Dfree%20interval.

We aregoing to know one way or the other whether if all the objectives of the trialsare met. Hoping for the best responses for the patients but if they don’t maybethe trials will find new therapeutics out of this OASIS trial.

OASIS Study Design from the ASCO Conference. You can find it on the Imugene website under Investors/Conference Presentation https://www.imugene.com/conference-presentations